Key Takeaway: Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in three healthcare conferences scheduled for November. The events will feature live and archived webcasts accessible on their website. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Price reaction · baseline $2.39 (2025-10-28 close) · hit pre-market · clean, no other ACRS news in the window
day 0 close · peak
-2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Aclaris Therapeutics is actively participating in multiple healthcare conferences.
The company is focused on developing novel treatments for immuno-inflammatory diseases.
Live webcasts will provide accessibility to a wider audience.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis
Full Press Release Details
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November.
Live and archived webcasts of these events will be accessible on theEvents pageofhttps://www.aclaristx.com/. The webcasts will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris onX(formerly Twitter) at @AclarisTx and onLinkedIn.